UCB's Antibody Technology Access Platform

UCB’s core Antibody Discovery Platform represents a highly efficient method to sample a natural immune repertoire, and the application of automation to some of the early stages of the process has improved reproducibility, accelerated timelines and increased capacity.

In order to enhance its collaborative networks and to stimulate research for the academic community, UCB subsequently launched a ‘Technology Platform Access’ programme, offering researchers the opportunity to access the platform to generate potential therapeutics or proof-of-concept tool reagents to further their research on potential antibody targets.

One of the first projects to enter the programme was a collaboration between two leading groups at the University of Oxford, one of UCB’s long-standing academic partners: the research groups of Alain Townsend, Professor of Molecular Immunology at the Weatherall Institute; and Simon Draper, Professor of Immunology and Infectious Disease at the Jenner Institute.

Following recent ebola virus outbreaks in West Africa, there has been considerable interest in generating new therapies, both vaccines and monoclonal antibody mixtures, directed against the ebola virus glycoprotein (EGP). UCB have been working with the teams at Oxford to produce large and diverse panels of anti-ebola virus neutralising antibodies.

Together more than 80 anti-EGP antibodies have been identified, from which a number of ‘cocktails’ are being tested with the help of Public Health England. The success of the project has led to further research into the discovery of antibodies which exhibit enhanced and broader strain neutralisation activity. This is being explored as a joint Oxford-UCB PhD.

For more information about the Technology Access Platform, visit: http://www.ucb.com/our-science/ourscience/tpap

For more information about accessing equipment belonging to a pharmaceutical company, search “Equipment/Resources” in ABPI LINC